EGQ0 Stock Overview
Engages in the developing and commercializing of diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
INOVIQ Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.28 |
| 52 Week High | AU$0.41 |
| 52 Week Low | AU$0.25 |
| Beta | 2.05 |
| 1 Month Change | 6.77% |
| 3 Month Change | 2.90% |
| 1 Year Change | n/a |
| 3 Year Change | -55.28% |
| 5 Year Change | -44.31% |
| Change since IPO | -5.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| EGQ0 | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | -9.6% | 0.7% | 0.6% |
| 1Y | n/a | 18.0% | 7.2% |
Return vs Industry: Insufficient data to determine how EGQ0 performed against the German Healthcare industry.
Return vs Market: Insufficient data to determine how EGQ0 performed against the German Market.
Price Volatility
| EGQ0 volatility | |
|---|---|
| EGQ0 Average Weekly Movement | 7.3% |
| Healthcare Industry Average Movement | 4.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: EGQ0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: EGQ0's weekly volatility has decreased from 13% to 7% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | Leearne Hinch | www.inoviq.com |
INOVIQ Ltd engages in the developing and commercializing of diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. The company offers hTERT test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an EV isolation tool for biomarker discovery and diagnostic development. Its cancer diagnostic pipeline includes internal and partnered diagnostic tests for improved screening, diagnosis, treatment selection and monitoring of cancer and other diseases.
INOVIQ Ltd Fundamentals Summary
| EGQ0 fundamental statistics | |
|---|---|
| Market cap | €32.58m |
| Earnings (TTM) | -€3.91m |
| Revenue (TTM) | €930.88k |
35.0x
P/S Ratio-8.3x
P/E RatioIs EGQ0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EGQ0 income statement (TTM) | |
|---|---|
| Revenue | AU$1.56m |
| Cost of Revenue | AU$2.78m |
| Gross Profit | -AU$1.22m |
| Other Expenses | AU$5.34m |
| Earnings | -AU$6.55m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.059 |
| Gross Margin | -78.07% |
| Net Profit Margin | -419.73% |
| Debt/Equity Ratio | 0% |
How did EGQ0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 08:37 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
INOVIQ Ltd is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Chris Kallos | MST Financial Services Pty Limited |